TIMP-3 expression associates with malignant behaviors and predicts favorable survival in HCC

Xuefeng Gu1, Maoying Fu1, Yuqin Ding1

  • 1Department of Infectious Diseases, The First People's Hospital of Kunshan Affiliated with Jiangsu University, Suzhou, China.

Plos One
|August 30, 2014
PubMed

Insights

Tissue inhibitors of metalloproteinases-3 (TIMP-3) are significantly decreased in hepatocellular carcinoma (HCC). Lower TIMP-3 expression correlates with advanced HCC, indicating its potential as a prognostic biomarker for improved patient survival.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Tissue inhibitors of metalloproteinases (TIMPs) regulate matrix metalloproteinases (MMPs).
  • TIMP-3 uniquely binds the extracellular matrix and acts as a tumor suppressor by inhibiting angiogenesis, invasion, and metastasis.
  • Hepatocellular carcinoma (HCC) is a major global health concern with a need for reliable prognostic markers.

Purpose of the Study:

  • To determine TIMP-3 expression levels in HCC.
  • To investigate the correlation between TIMP-3 expression and clinicopathological features in HCC patients.
  • To assess the prognostic value of TIMP-3 in HCC.

Main Methods:

  • Reverse transcription-polymerase chain reaction (RT-PCR) and Western blotting were used for cell line analysis.
  • Quantitative reverse transcription PCR (qPCR) and immunohistochemistry (IHC) analyzed TIMP-3 expression in HCC tissues.
  • Kaplan-Meier survival and Cox regression analyses evaluated prognosis in 101 HCC patients.

Main Results:

  • TIMP-3 expression was significantly lower in HCC tissues and cells compared to non-cancerous counterparts.
  • Reduced TIMP-3 expression was associated with portal vein invasion (p=0.036) and lymph node metastasis (p=0.030).
  • TIMP-3 expression emerged as an independent prognostic factor for disease-free survival (p=0.039) and overall survival (p=0.049).

Conclusions:

  • TIMP-3 expression is significantly downregulated in hepatocellular carcinoma.
  • TIMP-3 serves as a valuable independent prognostic biomarker for HCC.
  • Lower TIMP-3 expression predicts a less favorable prognosis, while higher expression suggests a better outcome for HCC patients.

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
7.5K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K